| Bioactivity | Fluorizoline selectively and directly binds to prohibitin 1 (PHB1) and 2 (PHB2), and induces apoptosis. Fluorizoline reduces chronic lymphocytic leukemia (CLL) cell viability through the upregulation of NOXA and BIM. Fluorizoline exerts antitumor action in a p53-independent manner[1]. | ||||||||||||
| Invitro | Fluorizoline (1.25-20 μM; 24 hours) induces apoptosis in primary CLL cells ex vivo[1]. Fluorizoline (5-10 μM; 48 hours) causes an increase of NOXA protein levels[1]. Fluorizoline reduces the percentage of viable normal B and T cells (48.6% and 82.8% of viable cells at 24 hours of treatment with 10 μM Fluorizoline in normal CD19+ and CD3+ populations, respectively) with mean EC50 values of 10.9 μM and 19.1 μM at 24 hours for normal B and T cells, respectively[1]. Apoptosis Analysis[1] Cell Line: | ||||||||||||
| Name | Fluorizoline | ||||||||||||
| CAS | 1362243-70-6 | ||||||||||||
| Formula | C15H8Cl2F3NS | ||||||||||||
| Molar Mass | 362.20 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Fluorizoline
CAS: 1362243-70-6 F: C15H8Cl2F3NS W: 362.20
Fluorizoline selectively and directly binds to prohibitin 1 (PHB1) and 2 (PHB2), and induces apoptosis. Fluorizoline red
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.